Sensorium Therapeutics gets FDA IND clearance for SNTX-2643, a first-in-class rapid-acting anxiolytic aimed at social anxiety disorder

SNTX-2643, Sensorium Therapeutics' lead anxiety program, received FDA clearance for an Investigational New Drug (IND) application, enabling first-in-human dosing. SNTX-2643 is positioned as a first-in-class precision serotonin modulator intended to treat neuropsychiatric conditions including social anxiety disorder (SAD). The company frames the compound as re-engineered from a natural product with a long history of human use, aiming for rapid onset of action, fewer off-target side effects, and avoidance of sedation often associated with benzodiazepine-like drugs. Sensorium also highlights that the drug's pharmacology is distinct from SSRIs, which can have delayed onset and may increase acute anxiety early in treatment. In parallel with the regulatory milestone, Sensorium appointed Jacob Hooker, PhD as CEO and Simba Gill, PhD as Executive Chair.